These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9517950)

  • 21. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.
    Bonacorsi SP; Scavizzi MR; Guiyoule A; Amouroux JH; Carniel E
    Antimicrob Agents Chemother; 1994 Mar; 38(3):481-6. PubMed ID: 8203841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.
    Campbell JL; Fay MP; Lanning LL; Hewitt JA
    Clin Infect Dis; 2020 May; 70(70 Suppl 1):S60-S65. PubMed ID: 32435805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
    Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
    J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model.
    Gur D; Glinert I; Aftalion M; Vagima Y; Levy Y; Rotem S; Zauberman A; Tidhar A; Tal A; Maoz S; Ber R; Pass A; Mamroud E
    Front Microbiol; 2018; 9():741. PubMed ID: 29740404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
    Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
    Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.
    Hewitt JA; Lanning LL; Campbell JL
    Clin Infect Dis; 2020 May; 70(70 Suppl 1):S51-S59. PubMed ID: 32435803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague.
    Vagima Y; Gur D; Aftalion M; Moses S; Levy Y; Makovitzki A; Holtzman T; Oren Z; Segula Y; Fatelevich E; Tidhar A; Zauberman A; Rotem S; Mamroud E; Steinberger-Levy I
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standardized Method for Aerosol Challenge of Rodents with Yersinia pestis for Modeling Primary Pneumonic Plague.
    Anderson PE; Olson RM; Willix JL; Anderson DM
    Methods Mol Biol; 2019; 2010():29-39. PubMed ID: 31177429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of several antibiotics and their combination with prodigiozan on Y. pestis EV, engulfed by macrophages].
    Popova GO; Vinidchenko NN; Mikhalevich RV; Sokolova MT; Makarovskaia LN
    Antibiotiki; 1977 Apr; 22(4):348-53. PubMed ID: 883789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
    Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
    Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
    Russell P; Eley SM; Green M; Stagg AJ; Taylor RR; Nelson M; Beedham RJ; Bell DL; Rogers D; Whittington D; Titball RW
    J Antimicrob Chemother; 1998 Feb; 41(2):301-5. PubMed ID: 9533478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pulmonic plague].
    Hovette P; Burgel PR; Camara P; Sane M; Auregan G; Klotz F
    Rev Pneumol Clin; 1998 Dec; 54(6):373-6. PubMed ID: 10100351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of monoclonal antibodies to plague microbe antigens at the early stage of infection in white mice for enhancement of the late streptomycin and doxycycline treatment].
    Ryzhko IV; Tsuraeva RI; Alekseeva LP; Shcherbaniuk AI; Mishan'kin MB
    Antibiot Khimioter; 2003; 48(3):21-5. PubMed ID: 12914117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.
    Sha J; Rosenzweig JA; Kirtley ML; van Lier CJ; Fitts EC; Kozlova EV; Erova TE; Tiner BL; Chopra AK
    Microb Pathog; 2013 Feb; 55():39-50. PubMed ID: 23063826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Treatment of Human Plague with Oral Ciprofloxacin.
    Apangu T; Griffith K; Abaru J; Candini G; Apio H; Okoth F; Okello R; Kaggwa J; Acayo S; Ezama G; Yockey B; Sexton C; Schriefer M; Mbidde EK; Mead P
    Emerg Infect Dis; 2017 Mar; 23(3):553-5. PubMed ID: 28125398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe].
    Shcherbaniuk AI; Liukshina EIu; Ryzhko IV; Smorodinova IuV
    Antibiot Khimioter; 2006; 51(1):7-10. PubMed ID: 16734358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model.
    Olson RM; Anderson DM
    PLoS One; 2019; 14(5):e0217440. PubMed ID: 31121001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague.
    Jakielaszek C; Hossain M; Qian L; Fishman C; Widdowson K; Hilliard JJ; Mannino F; Raychaudhuri A; Carniel E; Demons S; Heine HS; Hershfield J; Russo R; Mega WM; Revelli D; O'Dwyer K
    Sci Transl Med; 2022 Jun; 14(647):eabg1787. PubMed ID: 35648812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antimicrobial susceptibilities of strains of Yersinia pestis.
    Smith MD; Vinh DX; Nguyen TT; Wain J; Thung D; White NJ
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2153-4. PubMed ID: 8540736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathogenic properties of the toxin of Pasteurella pestis under the effect of some antibiotics. Protective and therapeutic effect of antibiotics in plague].
    Merinov SP; Vasil'eva ZI; Riabova GG
    Antibiotiki; 1970 Oct; 15(10):940-5. PubMed ID: 4321155
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.